Prosecution Insights
Prosecution Insights
Technology areas: Biotechnology & Pharmaceuticals • Chemistry & Materials • Medical Devices & Mechanical Engineering
4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Macquarie University is active in the Biotechnology & Pharmaceuticals technology area, where it currently manages 4 pending office actions. These 4 pending office actions are distributed across 4 distinct examiners and 4 distinct art units. This distribution indicates a highly diverse prosecution landscape, with each pending matter being reviewed by a different individual.
The busiest examiner for this portfolio is MALAMUD, DEBORAH LESLIE, who is responsible for 1 pending office action. Since there are 4 pending office actions in total, the workload is split among the 4 distinct examiners. This level of dispersion across 4 distinct art units suggests that the university's filings cover a broad range of technical applications within the Biotechnology & Pharmaceuticals field.
For practitioners, managing 4 pending office actions across 4 distinct examiners requires a multifaceted strategy. Each examiner may have different procedural preferences and interpretations of the prior art. The presence of MALAMUD, DEBORAH LESLIE as one of the examiners highlights the need for tailored responses that address the specific standards of each distinct art unit involved in the university's current prosecution.
Based on the USPTO statutory response window for each pending office action. 1 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (25%) |
| §112 only | 1 (25%) |
| Multi-statute (no §101) | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MALAMUD, DEBORAH LESLIE | 1 | 78.2% | +9.6% |
| FORSYTH, PAUL ALAN | 1 | 70.6% | +8.5% |
| NOBLE, MARCIA STEPHENS | 1 | 67.0% | +39.9% |
| FERGUSON, JALISA HOLMES | 1 | 61.1% | +43.8% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18558006 | A SURGICAL IMPLANT | MALAMUD, DEBORAH LESLIE | 30d |
| 17787007 | ALUMINOSILICATE GLASS | FORSYTH, PAUL ALAN | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 2 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17754597 | MODULATION OF CELLULAR VIABILITY | NOBLE, MARCIA STEPHENS | — |
| 17754135 | TREATMENT OF DEMENTIA | FERGUSON, JALISA HOLMES | — |
| Art Unit | Apps |
|---|---|
| 3792 | 1 |
| 1731 | 1 |
| 1632 | 1 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18558006 | A SURGICAL IMPLANT | MALAMUD, DEBORAH LESLIE | 3792 | §102§103 | Non-Final OA | 30d | Pending | Oct 30, 2023 |
| 17787007 | ALUMINOSILICATE GLASS | FORSYTH, PAUL ALAN | 1731 | §102§103 | Non-Final OA | — | Pending | Jun 24, 2022 |
| 17754597 | MODULATION OF CELLULAR VIABILITY | NOBLE, MARCIA STEPHENS | 1632 | §112 | Final Rejection | — | Pending | Apr 06, 2022 |
| 17754135 | TREATMENT OF DEMENTIA | FERGUSON, JALISA HOLMES | 1626 | §103 | Non-Final OA | — | Pending | Mar 24, 2022 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial